Advanced searches left 3/3

Focal - Crossref

Summarized by Plex Scholar
Last Updated: 25 June 2022

* If you want to update the article please login/register

Abstract B03: The EWS/FLI oncogene exerts pro-migratory and anti-apoptotic effects via dysregulation of focal adhesion kinase (FAK) signaling in Ewing sarcoma

Patients' greatest threat is likely to be patients, but earlier studies have shown that cytoskeletal rearrangements of EWS/FLI oncoprotein expression contribute to a migratory phenotype in ES cells. We show here that the most important tumorigenic effects of EWS/FLI are mediated by FAK autophosphorylation, as well as tumor cell migration, in addition to tumor cell migration, but poor caspase-3-mediated anoikis in vitro. Our findings, taken together, reveal that the etcogenic effects of EWS rearrangements are mediated by FAK autophosphorylation in ES, giving a reason for the use of FAK inhibitors to slow metastatic diffusion of ES. In:: Proceedings of the AACR International Conference: New Frontiers in Cancer Research, 2017 Jan 18-22; Cape Town, South Africa; 2017 Jan 18-22; Proceedings of the AACR International Conference: New Frontiers in Cancer Research, New Frontiers in Cancer Research; AACR International Conference: New Frontiers in Cancer Research; 2017 Jan 18-22.

Source link: https://doi.org/10.1158/1538-7445.newfront17-b03


Novel pathological abnormalities of deep brain structures including dysplastic neurons in anterior striatum associated with focal cortical dysplasia in epilepsy

Object And After epileptogenic cortical resection, some patients are not seizure free. The authors recently reported a case of frontal lobe epilepsy treated after the resection of periventricular white matter and striatum, in which dysplastic neurons were discovered. Methods They looked at the data of eight children with frontal lobe epilepsy who had daily or monthly seizures and underwent resections of deep brain structures. In the cortex and subcortical white matter of 5 patients, dysmorphic neurons were discovered. In three patients in whom dysmorphic neurons were dispersed, the striatum was confirmed.

Source link: https://doi.org/10.3171/2012.6.peds11325


Abstract CT103: A phase II study to evaluate outpatient magnetic resonance image-guided laser focal therapy for prostate cancer: A 20-year survival study (seven-year interim results)

Abstract Purpose: According to abstract statement: New prostate cancer cases in the United States alone for 2016 were estimated at 180,890 and deaths at 26,120. Low risk and moderate risk localized prostate cancer are both increasingly being investigated by researchers. In addition, new prostate cancer drugs for patients with biochemical recurrence are also under scrutiny. Our aim is to investigate the safety and success of using outpatient MR-guided laser focal therapy for MR visible prostate cancer, as well as a transrectal method for laser applicator placement and therapy delivery in a outpatient clinic. Method and Materials: All MRI-guided therapy was delivered using a 1. 5 Tesla MRI system for both image capture and real-time thermometry. The number of coagulation necrosis ranged from 0. 57 to 22. 93 cc during the surgery. At six months biopsy, we saw a 40% decrease in mean PSA, consistent with residual or recurrent cancer 26% of subjects and no statistically significant change in IPSS and SHIM at 6 months post-treatment. Conclusion: Our results show that outpatient, transrectally administered MRI-guided laser focal therapy for prostate cancer is both safe and effective. Clinical relevance/Application: Application: In the current climate of cost-cutting and a focus on minimally-invasive cancer treatment, a focal treatment of prostate cancer may be a viable option. A 20-year survival study [abstract]: A phase II research to assess outpatient magnetic resonance image-guided laser focal therapy for prostate cancer.

Source link: https://doi.org/10.1158/1538-7445.am2017-ct103


Management and outcome of focal low-grade brainstem tumors in pediatric patients: the St. Jude experience

Object Whereas diffuse intrinsic pontine gliomas have a short clinical duration and greater cranial nerve involvement, focal brainstem gliomas have a low incidence, with less cranial neuropathies. The aim of this paper was to describe the diagnosis and treatment of these tumors because there is a lack of literature on pediatric focal brainstem gliomas. Methods The authors reviewed the records of all children diagnosed with low-grade focal brainstem gliomas from 1986 to 2010. Within 25. 1 months of diagnosis, disease progression in the other 19 patients occurred within 25. 1 months of diagnosis. Although children with intrinsic tumors had marginally better EFS at 5 years compared to those with exophytic tumors, this difference was not significant at ten years, according to children with intrinsic tumors. Conclusions In several children with low-grade focal brainstem gliomas, surgery suffices. Radiation therapy is often reserved for disease progression, but it does provide similar disease control following biopsy.

Source link: https://doi.org/10.3171/2012.11.peds12317


Seizure outcome of surgical treatment of focal epilepsy associated with low-grade tumors in children

The most effective surgical care of epileptogenic LGTs in pediatric patients has yet to be established. Patients in Group A underwent only tumor removal, while patients in Group B underwent surgical resection of the tumor and the adjacent epileptogenic zone. Results Sixteen of the twenty 20 patients in Group A had an Engel Class I event. 3 of the four children in Engel Classes II and III had temporomesial lesions. All patients in Group B had temporomesial tumors and were seizure free. In addition, a young age at seizure onset was related to poor seizure outcomes. Conclusions Tailored resection in temporomesial LGTs resulted in a positive seizure response, indicating that an accurate presurgical assessment alongside extensive neurophysiological testing is recommended to determine the most appropriate surgical strategy.

Source link: https://doi.org/10.3171/2012.11.peds12137


Detection of epileptogenic focus using advanced dynamic statistical parametric mapping with magnetoencephalography in a patient with MRI-negative focal cortical dysplasia type IIB

Two type I seizures originating from the right frontocentral area of Scalp video-electroencephalography were caught on camera by electroencephalography. The spike source at the bottom of the right inferior frontal sulcus was identified by AdSPM. One type I seizure was found during the Intracranial video-EEG, which resulted from the depth electrode at the bottom of the sulcus and linked to the AdSPM spike source. The patient had focal cortical dysplasia type IIB, according to a Histopathological examination. Since receiving topiramate therapy, the patient has been seizure free for two years. AdSPM is the first published preliminary study to show MRI-negative epilepsy.

Source link: https://doi.org/10.3171/2019.7.peds1948


Abstract 5812: MIEN1 promotes breast cancer cell migration and invasion by regulating cytoskeletal dynamics via focal adhesion kinase and N-WASP

Abstract Short Description: Migrant 1 and Invader 1 is a significant regulator of cell migration and invasion. Abstract: Description of the text: Short summary of migration and invasion: Migration and invasion enhancer 1 is a key influencer of cell migration and invasion. MIEN1 overexpression is an oncogenic event that promotes tumor cell proliferation and metastasis. MIEN1 is a cytoskeletal-signaling adapter protein that promotes breast cancer cell migration, according to our findings. Also decreased the cell-substratum adhesion, suggesting a role for MIEN1 in actin cytoskeletal dynamics. Our findings indicate that MIEN1 supports the conversion of G-actin polymerization from F-actin polymerization to F-actin polymerization and stabilizes F-actin polymers. In addition, MIEN1 promotes cell adhesion and actin dynamics by inducing FAK phosphorylation at Tyr-925 and lowering cofilin phosphorylation at Ser-3, which results in breast cancer cell migration. Hence, targeting MIEN1 could be a promising way to discourage breast tumor metastasis. MIEN1 promotes breast cancer cell migration and invasion by controlling cytoskeletal parameters through focal adhesion kinase and N-WASP [abstract].

Source link: https://doi.org/10.1158/1538-7445.am2017-5812


Abstract 5194: Focal radiation enhances paclitaxel therapy in a mouse model of triple negative breast cancer

Abstract Accessed Triple negative breast cancer accounts for 15-20% of all breast cancers in the United States. We investigated whether a combination of focal RT and paclitaxel would increase anti-tumor activity in comparison to paclitaxel alone. We compared a low dose fractionated diet to a more effective but less frequent regimen either as monotherapy or in combination with paclitaxel, using the Small Animal Radiation Research Platform. In both radiation regiments, the total dose of radiation was 24-25Gy. With a ten-day tumor growth delay and no tumor regressions, Paclitaxel alone delivered moderate to moderately daily with a 10-day tumor growth delay and no tumor regressions. Tumor stasis was seen in tumor stasis for u226568 days, but there were no tumor regressions or tumor free survivors despite a lack of tumor immunologists or tumor-free survivors. A 75% chance of suspected partial regressions and a 25% risk of complete regressions with no TFS were present in Treatment with 8Gy. Mean BWL was 10. 1 percent with a nadir around 8-10 days after first RT dose, with a nadir in a nadir. Low dose focal RT with paclitaxel resulted in a similar pattern as high dose radiation induced activity. On study day 108, paclitaxel plus 8Gy RT was highly effective, resulting in an 80% risk of CRs, with 80% of CRs, all of whom were tumor free. Hence, a higher dose of focal RT administered in shorter intervals in combination with systemic paclitaxel resulted in the most cost-effective therapeutic scheme, but at the expense of increased BWL and clinical signs. In a mouse model of triple negative breast cancer [abstract], foil radiation improves paclitaxel therapy.

Source link: https://doi.org/10.1158/1538-7445.am2017-5194


Abstract 4884: Focal 22q11.22 deletions combined with IKZF1 alterations are associated with worse clinical outcome in acute lymphoblastic leukemia

Abstract: Prognostic biomarkers in childhood acute lymphoblastic leukemia are critical in preventing risk stratification and intensifying therapy for children at risk of remission induction failure or relapse. Copy number changes in genes such as IKZF1 and VPREB1 have been shown to be correlated with poor outcomes in all, highlighting genetic variations as prognostic markers. A second focal deletion in chromosome 22q11. 22, 200 kilobases in length, appears more often and in the same IGLL region as VPREB1; it is distinct from deletions associated with physiologic IGLL rearrangement. Results: In about 30-45% of each cohort, Utah = 49%, TARGET = 29 percent, CHOP = 34 percent, and DS = 47. 7%. In about 10-15% of each cohort, Utah = 12. 5%, SJCRH = 8. 4%, CHOP = 6. 4%, DS = 14. 4%, and DS = 14. 4%. TARGET = 0. 63 years, P= 0. 0001; 0. 0001, SJCRH = 102, P= 0. 001, and P= 0. 0001. Conclusion: We now have further evidence that non-physiological deletions within the IGLL locus is related to poor outcomes in pediatric ALL, and when combined with IKZF1, a population of patients with very poor results is identified. Multiple clinical outcomes in acute lymphoblastic leukemia are attributed to Focal 22q11. 22 deletions as well as IKZF1 alterations [abstract].

Source link: https://doi.org/10.1158/1538-7445.am2017-4884


Abstract 4712: Image-guided focal irradiation in syngeneic preclinical oncology mouse models

Abstract The use of image-guided focal irradiation is a keystay of human cancer therapy. Targeted focal irradiation can now be used in a variety of preclinical oncology models thanks to the emergence of image-guided small animal irradiators, such as the Small Animal Radiation Research Platform. Following focal irradiation alone or in combination with immune protection, the research presented here assesses tumor responses in a number of syngeneic tumor models. The A20 and RIF1 mice tumor models as well as an intracranial GL261-luc model were tested for bilateral subcutaneous mouse tumor models. Both right and left side implants were implanted in the SC models, so focal irradiation was only to the right side of tumors and tumor formation changes were reported. RIF1 is a more radiation resistant model, and a single bolus dose of 10Gy only marginally reduced tumor burden on the right side tumors, but not so on the contralateral tumors. A single bolus dose of 15Gy was curative, while 10Gy resulted in 60-75% mortality over the study period. In a follow-up study, we discovered that a combination of 10Gy focal radiation and systemic anti-PD-1 antibody therapy could enhance overall survival over monotherapy. Radiation therapy has been shown to improve tumor antigen presentation and variety of peptides available for cross-presentation in mouse models. Current research in the field emphasizes using radiation to bridge the transition from tumor equilibrium to tumor elimination, which may increase the response rate of immuno-oncology agents.

Source link: https://doi.org/10.1158/1538-7445.am2017-4712

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions